| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | 0.19 | 0.0002 |
| mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0004 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | 0.23 | 0.001 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.004 |
| mRNA | JQ-1:MK-0752 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.095 | 0.005 |
| mRNA | Z-LLNle-CHO | GDSC1000 | pan-cancer | AAC | 0.15 | 0.006 |
| mRNA | Nutlin-3 | CTRPv2 | pan-cancer | AAC | 0.095 | 0.006 |